TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12053587

Group type: EXPERIMENTAL
Intervention: Phonatory and respiratory function studies including MPT, MFR, PV, PQ, VVI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five physiologic criteria for laryngeal function evaluation
Number of subjects: 0
Study: 10606323

Group type: EXPERIMENTAL
Intervention: CIFN 9 microg
Number of subjects: 472

Group type: COMPARATOR
Intervention: IFN alpha‐2b 3 MU
Number of subjects: 472
Study: 8984859

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with 2.5 micrograms.ml‐1 fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% alone
Number of subjects: 0
Study: 1754638

Group type: EXPERIMENTAL
Intervention: Green light treatment (2 hours each morning for 1 week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White light treatment (2 hours each morning for 1 week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sequence of treatment conditions
Number of subjects: 12
Study: 7428802

Group type: EXPERIMENTAL
Intervention: Fluoride 3.0 mg as sodium fluoride tablets during acid urine production (induced by NH4Cl)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluoride 3.0 mg as sodium fluoride tablets during alkaline urine production (obtained by NaHCO3)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control experiments without F administrations
Number of subjects: 5
Study: 31238808

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 124

Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 124
Study: 31083046

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) for 5 minutes targeting the gastrocnemii, soleus, tibialis posterior muscles, deep fascia, and Achilles tendon.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (rest for 5 minutes without IASTM).
Number of subjects: 14
Study: 28586162

Group type: EXPERIMENTAL
Intervention: DP10-60 ITF (8 g/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DP2-25 ITF (8 g/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fructose placebo (8 g/day)
Number of subjects: 40
Study: 26453560

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 23325283

Group type: EXPERIMENTAL
Intervention: RFA+HS (hypertonic saline-enhanced radiofrequency)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TACE+RFA (transarterial chemoembolization followed by radiofrequency)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RFA+HS
Number of subjects: 40

Group type: COMPARATOR
Intervention: TACE+RFA
Number of subjects: 40
Study: 17257231

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg/min for 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15036742

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32-34 degrees C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normothermic therapy
Number of subjects: 15
Study: 10660238

Group type: EXPERIMENTAL
Intervention: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) with clonidine 4.5 microg/mL (group BFC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) without clonidine (group BF)
Number of subjects: 75
Study: 9303508

Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) 9 microg
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) 3 microg
Number of subjects: 704

Group type: COMPARATOR
Intervention: Recombinant interferon alfa-2b (IFN-alpha2b) 15 microg
Number of subjects: 704
Study: 8346818

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.7%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enflurane (0.9%)
Number of subjects: 38
Study: 2871945

Group type: EXPERIMENTAL
Intervention: MPA (500 mg b.i.d. for 6 months)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: CT + MPA
Number of subjects: 227

Group type: COMPARATOR
Intervention: CT + placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 227
Study: 30591153

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 210

Group type: COMPARATOR
Intervention: Light-cured composite
Number of subjects: 210
Study: 29522149

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 26
Study: 26274985

Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%)
Number of subjects: 112
Study: 25511185

Group type: EXPERIMENTAL
Intervention: App-delivered relaxation techniques (autogenic training, mindfulness meditation, or guided imagery) practiced at least 5 days/week for 15 minutes/day over 6 months.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 220
Study: 23268821

Group type: EXPERIMENTAL
Intervention: Transportal TransFix®
Number of subjects: 168

Group type: COMPARATOR
Intervention: Transtibial TransFix®
Number of subjects: 168
Study: 19023152

Group type: EXPERIMENTAL
Intervention: Low-dose abciximab (0.20 mg/kg bolus followed by 12-h infusion)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: High-dose abciximab (0.25 mg/kg bolus followed by 12-h infusion)
Number of subjects: 973

Group type: COMPARATOR
Intervention: Placebo (bolus and infusion of placebo)
Number of subjects: 973
Study: 17227669

Group type: EXPERIMENTAL
Intervention: merthiolated antigen
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: phenolated antigen
Number of subjects: 400

Group type: COMPARATOR
Intervention: merthiolated saline
Number of subjects: 400

Group type: COMPARATOR
Intervention: phenolated saline
Number of subjects: 400
Study: 16194314

Group type: EXPERIMENTAL
Intervention: Preservation of intercostobrachial nerve
Number of subjects: 162

Group type: COMPARATOR
Intervention: No preservation of intercostobrachial nerve (Control)
Number of subjects: 162
Study: 11927177

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 9456098

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 230

Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 230
Study: 7702228

Group type: EXPERIMENTAL
Intervention: Interferon‐α2b
Number of subjects: 552
Study: 2242740

Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani 3 1 and 4 1
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani 2 1
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Iso‐Giuliani
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 191
Study: 362234

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study: 31930338

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not experiencing a CVD event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASCVD risk tertiles
Number of subjects: 0
Study: 31151245

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: WHtR(exp)
Number of subjects: 1036
Study: 28053257

Group type: EXPERIMENTAL
Intervention: Knee joint distraction (KJD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 60
Study: 25387805

Group type: EXPERIMENTAL
Intervention: Sleep hygiene and artificial bright light interventions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 13
Study: 23494021

Group type: COMPARATOR
Intervention: Nerve stimulation group (NS)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance group (US)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS1
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS2
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nerve stimulation subgroup NS3
Number of subjects: 250
Study: 21046232

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No aromatase inhibitors (no AIs)
Number of subjects: 82
Study: 19081397

Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel
Number of subjects: 256

Group type: COMPARATOR
Intervention: 300-mg loading dose of clopidogrel
Number of subjects: 256
Study: 17955563

Group type: EXPERIMENTAL
Intervention: Cox regression model for cause-specific hazard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine and Gray regression model for subdistribution hazard
Number of subjects: 0
Study: 16390629

Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles containing 30 mg Fe/day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 11276275

Group type: EXPERIMENTAL
Intervention: Potent pancreatic enzyme supplement (4 capsules with meals, 2 with snacks; lipase 10,000 USP units, protease 37,500 units, amylase 33,200 units)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (after enzyme supplementation)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active enzyme supplementation (after placebo)
Number of subjects: 29
Study: 9624697

Group type: EXPERIMENTAL
Intervention: Intracanalicular silicone plugs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rewetting drops with plugs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rewetting drops
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 35
Study: 7933491

Group type: EXPERIMENTAL
Intervention: Ephedrine (EP) 0.15 mg.kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine (PH) 2 micrograms.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (EP and PH)
Number of subjects: 30
Study: 2851177

Group type: EXPERIMENTAL
Intervention: Vindesine and cisplatin (VP)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 233
Study: 29208402

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 110

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 110
Study: 27625146

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg, local submucosal injection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline solution, local submucosal injection)
Number of subjects: 60
Study: 25080594

Group type: EXPERIMENTAL
Intervention: Adaptation to altered auditory feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory feedback that subjects received during learning
Number of subjects: 0
Study: 23064980

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Static Handgrip Exercise (HG)
Number of subjects: 20
Study: 20940690

Group type: EXPERIMENTAL
Intervention: Treatment with carnitine, acetyl carnitine, L-arginine and ginseng
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 180
Study: 18095903

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study: 15876900

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12522383

Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment questionnaire
Number of subjects: 257
Study: 11305547

Group type: EXPERIMENTAL
Intervention: Metronidazole 2 g suppository
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 9369820

Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin (4 mg/kg IV every 24 hours) with twice-daily clindamycin (1200 mg IV every 12 hours)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Thrice-daily gentamicin (1.33 mg/kg IV every 8 hours) with clindamycin (800 mg IV every 8 hours)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin with twice-daily clindamycin
Number of subjects: 272

Group type: COMPARATOR
Intervention: Thrice-daily gentamicin with clindamycin
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 272
Study: 1578946

Group type: EXPERIMENTAL
Intervention: Monthly myelosuppressive maintenance for 3 years after initial TAD treatment in the 1981 study.
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Second induction course for all patients up to 60 years of age in the 1985 study.
Number of subjects: 674

Group type: COMPARATOR
Intervention: Auto-BMT in first complete remission (CR) as per the 1985 protocol.
Number of subjects: 674
Study: 6738937

Group type: EXPERIMENTAL
Intervention: Long-acting prostaglandin suppository (9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 95
Study: 31101439

Group type: EXPERIMENTAL
Intervention: Energy-restricted Mediterranean diet
Number of subjects: 6646

Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 6646

Group type: EXPERIMENTAL
Intervention: Non-smoking lifestyle
Number of subjects: 6646

Group type: EXPERIMENTAL
Intervention: Avoidance of sedentary lifestyles
Number of subjects: 6646
Study: 31478290

Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. essential oil (CuEO) 75 mg, thrice daily for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo soft gel, thrice daily for 8 weeks
Number of subjects: 56
Study: 25546488

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program plus oral medication
Number of subjects: 146

Group type: COMPARATOR
Intervention: Oral medication alone
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program
Number of subjects: 146
Study: 24880917

Group type: EXPERIMENTAL
Intervention: Balance and technique training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 28
Study: 23680986

Group type: EXPERIMENTAL
Intervention: Experience Corps™ (senior volunteer roles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience Corps™ (for children)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual volunteering opportunities (control for older adults)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched, eligible control schools (control for children)
Number of subjects: 0
Study: 20868637

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 19246733

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cephradine (500 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril and Cephradine co-administration
Number of subjects: 9
Study: 17122621

Group type: EXPERIMENTAL
Intervention: Early nasogastric enteral nutrition (EN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 50
Study: 12648302

Group type: EXPERIMENTAL
Intervention: Brimonidine Purite 0.15% BID
Number of subjects: 407

Group type: COMPARATOR
Intervention: Brimonidine 0.2% BID
Number of subjects: 407
Study: 10505743

Group type: EXPERIMENTAL
Intervention: IFN therapy
Number of subjects: 24
Study: 8726600

Group type: EXPERIMENTAL
Intervention: Combination therapy with lovastatin 20 mg/day and niacin 500 mg 3 times/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lovastatin 40 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lovastatin 20 mg/day
Number of subjects: 28
Study: 2011669

Group type: EXPERIMENTAL
Intervention: Six-month rehabilitation programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine cardiac follow-ups
Number of subjects: 116
Study: 7302311

Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 160
Study: 6465160

Group type: EXPERIMENTAL
Intervention: Aspirin (2,400 and 3,900 mg/day)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Ibuprofen (1,200 mg/day)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2,400 mg/day)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1,600 mg/day for three days)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ibuprofen (4,800 mg/day)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Naproxen, tolmetin sodium, indomethacin (larger doses)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Placebo, pro drugs, enteric-coated aspirin
Number of subjects: 843
Study: 29315944

Group type: EXPERIMENTAL
Intervention: Saline mouth rinse regimen and education programme
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study: 26209587

Group type: EXPERIMENTAL
Intervention: PG324 0.02%
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: PG324 0.01%
Number of subjects: 298

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 298

Group type: COMPARATOR
Intervention: AR-13324 0.02%
Number of subjects: 298
Study: 24769600

Group type: EXPERIMENTAL
Intervention: Procarbazine, lomustine, and vincristine (PCV) chemotherapy combined with standard radiation therapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard course of radiation therapy (RT)
Number of subjects: 0
Study: 22884055

Group type: EXPERIMENTAL
Intervention: Early PDT
Number of subjects: 119

Group type: COMPARATOR
Intervention: Late PDT
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study: 20377116

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily for 2 weeks
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 577
Study: 17906931

Group type: EXPERIMENTAL
Intervention: Usual care plus intervention with a patient navigator
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 16359417

Group type: EXPERIMENTAL
Intervention: CPDA-1 RBC stored for up to 28 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: CPDA-1 RBC stored for up to 3 days
Number of subjects: 52
Study: 12484804

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 100000
Study: 10583351

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 180
Study: 8923037

Group type: EXPERIMENTAL
Intervention: Anticarcinogenic agent (specific agent not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled trial
Number of subjects: 0
Study: 1909810

Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral natural micronized progesterone
Number of subjects: 80
Study: 6666842

Group type: EXPERIMENTAL
Intervention: Methylmethacrylate
Number of subjects: 10

Group type: COMPARATOR
Intervention: BDF cement
Number of subjects: 10
Study: 30204734

Group type: EXPERIMENTAL
Intervention: Vitamin D replacement only (Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical excision and suturation after vitamin D replacement (Group 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Group 1)
Number of subjects: 50
Study: 28753838

Group type: EXPERIMENTAL
Intervention: pT3b-4, Gleason score ≥8, pN1 as independent predictors of prostate cancer-related death (PCRD)
Number of subjects: 2823

Group type: EXPERIMENTAL
Intervention: Cross-validation of the model
Number of subjects: 2823
Study: 27938852

Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 26376

Group type: EXPERIMENTAL
Intervention: Lisinopril (L)
Number of subjects: 26376

Group type: COMPARATOR
Intervention: Chlorthalidone (C)
Number of subjects: 26376
Study: 24291151

Group type: EXPERIMENTAL
Intervention: ATLAS intervention (8-month multi-component school-based program)
Number of subjects: 0
Study: 22466821

Group type: EXPERIMENTAL
Intervention: Low tidal volume (V(T) 5 ml kg(‐1)) with high PEEP
Number of subjects: 88

Group type: COMPARATOR
Intervention: Larger tidal volume (V(T) 8 ml kg(‐1)) with low PEEP
Number of subjects: 88
Study: 20880345

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (E/S) + extended-release niacin (N)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: N
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin (E/S)
Number of subjects: 1220
Study: 17659904

Group type: EXPERIMENTAL
Intervention: Lifestyle case management
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 16541972

Group type: EXPERIMENTAL
Intervention: Bee venom extract
Number of subjects: 9
Study: 14739714

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 1450
Study: 10515518

Group type: EXPERIMENTAL
Intervention: 12-week clinician-implemented language intervention program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delayed-treatment group (Control)
Number of subjects: 21
Study: 8746601

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Diet + Exercise intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Triglycerides, HDL cholesterol, and insulin variables
Number of subjects: 219
Study: 2042788

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) infusion (7 mg/kg bolus followed by 10 mg/kg/h continuous infusion)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg/min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Concurrent MgSO4 and epinephrine administration
Number of subjects: 17